文献速递瓣膜外科

二尖瓣手术同期外科消融房颤可改善生存

Enhanced Survival With Surgical Ablation of Atrial Fibrillation During Mitral Valve Surgery.
PubMed 文献 · Ann Thorac Surg · 2025-02-12

该研究基于2008-2019年Medicare索赔数据,纳入41,795例既往房颤并接受二尖瓣手术的受益人,采用重叠倾向评分加权和工具变量分析。结果显示,同期外科消融与风险调整后中位生存期延长相关,且由高频消融外科医生手术亦与生存改善相关。

要点

  • 二尖瓣手术同期外科消融与风险调整后中位生存期延长0.56年相关。
  • 由高频消融外科医生手术与中位生存期延长0.35年相关。
  • 按外科医生偏好分析的治疗效应与按治疗分析存在差异,提示未测量混杂可能。

核心结论

  • 在既往房颤的Medicare受益人中,二尖瓣手术同期外科消融与生存改善相关。
  • 由高频进行外科消融的外科医生手术亦与生存改善相关。
  • 基于外科医生偏好的分析显示治疗效应的幅度和时间依赖性可能与按治疗分析不同,提示按治疗分析可能受未测量混杂偏倚影响。

研究设计与样本

  • 回顾性队列研究,查询2008-2019年Medicare索赔数据,识别既往房颤并接受二尖瓣手术的受益人。
  • 共纳入41,795例受益人,采用重叠倾向评分加权进行风险调整。
  • 另以外科医生外科消融频率作为工具变量,调整未测量混杂变量。

主要发现

  • 外科医生分为低频消融组(底部四分位,<30%;10,364例受益人)和高频消融组(顶部四分位,≥62%;10,476例受益人)。

临床怎么用

  • 对于既往房颤接受二尖瓣手术的患者,可考虑同期行外科消融以改善生存。
  • 外科医生消融频率与患者生存改善相关,提示经验积累可能影响治疗效果。

局限性

  • 研究为回顾性分析,尽管采用倾向评分加权和工具变量法,仍可能存在未测量混杂。
  • 按治疗分析与按外科医生偏好分析的结果存在差异,提示治疗效应估计可能受分析方法影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Surgical ablation (SA) at the time of isolated mitral valve surgery (MVS) is recommended in patients with preexisting atrial fibrillation (AF). However, SA remains infrequently utilized during MVS with a poorly quantified impact on stroke and survival. METHODS: Medicare claims (2008-2019) were queried to identify beneficiaries with preexisting AF undergoing MVS. All-cause mortality and the postoperative incidence of stroke/transient ischemic attack were evaluated as separate endpoints. Overlap propensity score weighting was used to risk-adjust for measured confounding variables. Analyses were repeated using surgeon frequency of SA as an instrumental variable to adjust for unmeasured confounding variables. RESULTS: From 2008-2019, 41,795 Medicare beneficiaries with a preexisting diagnosis of AF underwent MVS. Surgeons were categorized, with 1326 infrequently (bottom quartile) performing SA (<30%; 10,364 beneficiaries) and 740 frequently (top quartile) performing SA (≥62%; 10,476 beneficiaries) during MVS. Beneficiaries undergoing MVS with SA ("as-treated" analysis) had a risk-adjusted median survival advantage of 0.56 (95% CI, 0.33-0.81) years (8.85 [95% CI, 8.64-9.04] vs 8.29 [95% CI, 8.11-8.47] years, P < .001 for risk-adjusted survival comparison) compared to those without. Beneficiaries undergoing MVS by frequent SA surgeons ("surgeon-preference" analysis) had a risk-adjusted median survival advantage of 0.35 (95% CI, 0.05-0.71) years (8.59 [95% CI, 8.40-8.85] vs 8.24 [95% CI, 7.97-8.40] years, P = .0015 for risk-adjusted survival comparison) compared to surgeons who infrequently performed SA. CONCLUSIONS: In Medicare beneficiaries with preexisting AF, concomitant SA during MVS is associated with improved survival, as is undergoing surgery by a frequent SA surgeon. When analyzed based on surgeon preference for SA, the magnitude and time-dependent nature of the treatment effect of SA were substantially different compared to the "as-treated" analysis, suggesting that "as-treated" analyses may be subject to bias from unmeasured confounding variables.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Eisenga JB, McCullough KB, Banwait JK, et al. Enhanced Survival With Surgical Ablation of Atrial Fibrillation During Mitral Valve Surgery. Ann Thorac Surg. 2025. PMID: 39952581. doi:10.1016/j.athoracsur.2025.01.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。